Ensysce completes PF614-MPAR-102 enrollment
Analysis based on 6 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The completion of enrollment is a positive clinical milestone for Ensysce, potentially boosting investor confidence in its pipeline. However, as a clinical-stage company, the impact is limited until regulatory approval and commercialization are achieved.
Forte Biosciences, a clinical-stage biotechnology company, announced completion of enrollment in the final stage (Part 3) of its PF614-MPAR-102 clinical study. The study evaluates its MPAR (Multi-Pill Abuse Resistance) overdose-protection technology, designed to limit opioid release at excessive doses while maintaining therapeutic levels at normal doses. The program has Breakthrough Therapy designation from the FDA. The study is supported by the United States — National Institute on Drug Abuse (NIDA) under award DA047682. CEO Lynn Kirkpatrick highlighted the potential to address the opioid overdose crisis, noting nearly 80,000 U.S. deaths annually. Ensysce is also developing TAAP analogues for amphetamine and methadone and a psychedelic program for Complex Regional Pain Syndrome.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard